Capstone Holding Corp. (CAPS) Stock
Basic Materials · Construction Materials · US
$0.37
+22.60%
Last updated Jun 18, 2026 23:52 UTC
CAPS Key Statistics
Market Cap$2.02M
P/E (TTM)-0.09
P/S (TTM)0.04
P/B (TTM)0.16
Revenue (TTM)$46.88M
EPS (TTM)$-4.12
Dividend Yield—
ROE (TTM)-94.49%
Net Margin-46.79%
Gross Margin23.02%
52W High$0.89
52W Low$0.26
Analyst ViewBuy
Price Target—
Employees36
Volume117,850,222
About Capstone Holding Corp.
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.
CEO: Matthew E. Lipman. Company website
See CAPS live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open CAPS in Terminal See plans